ǿʹ¶¨,FortanodynÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÕòÍ´Ò©Îï,analgesicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ë«ÖÖȺÒÅ´«Ëã·¨,DPGAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖнéÌå,intermediaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÈÈÁÆ,thermotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö°©»úÀí,carcinogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÐÏÞ±ÊÊø,fsPBÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ß»à«à­ßøÍª,FuroquinolinoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó¦¼¤ÓÕµ¼µÄÌáǰ˥ÀÏ,SIPSÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ßÅßáͪ,1-(2,6-Dichlorophenyl)-2-indolinoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ŵ˹¿¨Æ·,opianineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó²ÏËάÁö,desmoidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢Áܰ͹ÜÉú³É,lymphangiogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö¸ú×Ù,tumour-trackingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©»ùÒòÓÕµ¼µÄË¥ÀÏ,OISÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó¡¶È´«Í³,AyurvedicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶òÂÞÌæÄá,erlotinibÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÊÐÎÕÕÉä,conformalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò»¹ýÐÔÉý¸ß,Flare-upÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Òí×´æÀÈâ/²¡Òòѧ,pterygium/etiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èí¹ÇÈâÁö/²¡Àíѧ,chondrosarcoma/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ûÌ¥Áö/Õï¶Ï,Teratoma/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·´Ê½¶þôÇ»·Ñõ±½²¢ÜÅ,anti-benzo(a)pyrene-trans-7,8-dihydrodio1-9,10-epoxideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« P-gpÌǵ°°×,p-glycoproteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁªºÏ·Å»¯ÁÆ,luxi-therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ­¸Ç¹Ç,calvariumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ƥ·ôÏËάÈâÁö/Õï¶Ï,Dermatofibrosarcoma/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºáÎÆ¼¡ÈâÁö/Õï¶Ï,Rhabomyosarcoma/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·¸Ç¿Ë,galakeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö²¡Òòѧ,neoplasma/etiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼×»ù±ûÏ©õ£×ϲÝËØ,methylacryloylshikoninÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éú´æËØ¿¹Ìå,anti-survivinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ĥ½áºÏÐÍǰÁÐÏÙËØEºÏ³Éø1,mPGES-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ïû̵ɢ½á,XiaotansanjieÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÄÁ¼ÀÏÄê¼²²¡ÀÛ¼ÆÆÀ·Ö±í,MCIRS-GÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×¼¤Ã¸C¦Â,PKC¦ÂÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©Àíͨ,AilitongÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÁܰ͹ÜÁö,hematolymphangiomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×ϸ°ûÔö¶àÖ¢,leukocytosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸º·´À¡µ÷½Ú,iHATSÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ç¿»¯Èںϵ°°×,ER(Fv-LDP-AE)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« 2-¼×»ù-Õý¶¡õ£×ϲÝËØ,(2-Methyl-n-butyl)shikoninÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹Ü×è¶Ï,vascular-disruptingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÉÈÜÐÔB7-H4,sB7-H4Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÛÏ»ù¶þïÌú,6-ferrocenylhexanethiollÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ËÄÝÁ»ù߲߸,tetranaphthylporphyrinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ç»»ýÒº¨M¶ñÐÔ,ascites/malignantÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·öÕýºÏ¼Á,Fuzheng-drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ûÌ¥°©ÑÜÉúÉú³¤Òò×Ó-1,TDGF-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âܲ·ÁòÜÕ,glucoraphaninÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« º£ÇÊ´¼ÑÜÉúÎï002,SC002Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒȵºËØÑùÉú³¤Òò×Ó¢ò mRNA½áºÏµ°°×3,IMP3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« EºÐ½áºÏпָµ°°×,ZEBÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÒ¶þ°·Àà/Ò©Àíѧ,ethylenediamines/pharmacolÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« îÌ/Ò©Àíѧ,samarium/pharmacolÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MRP14µ°°×,MRP14Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ä¶¾ëÄ/Ò©Àíѧ,melitten/pharmacologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÔÙÉú/Ѫ¹Ü·¢Éú,angiogenesis/vasculogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¡ÀíÐÔ/²¡ÀíÉúÀíѧ,pathologic/physiopatholÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« E-cadherin/catenin¸´ºÏÎï,E-cadherin/cateninComplexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« à­¿Ú¶ñßø-1,4-Ñõ»¯Îï,quinoxaline-1,4-oxideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼×»ù߻ૺËÜÕ,methylfuranonucleosideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÏɼëÄ,paclitaxtideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÕûºÏËØÁ¬½Ó¼¤Ã¸Ïà¹ØÁ×Ëáø,ILKAPÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¯Ì¬µ÷Ç¿·ÅÁÆ,dynamicintensity-modulatedradiationtherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±½²¢ßÁà«Íª,chromoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 1,4,5,8-ËÄôÇ»ùÝìõ«ÒþÉ«Ìå,leuco-1,4,5,8-tetrahydroxyanthraquinoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏËάÈâÁö/²¡Àíѧ,Fibrosarcoma/patholÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éú³¤µ÷½ÚÖ°©»ùÒò-1,GRO-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ºËµ°°×-¦Ã,Synuclein-gama(¦Ã-syn)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÍâ»ùÖÊ»î»¯ËØ,matrikinesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔÆÄÏÃ¹ËØ-RGD¶þ¼×õ¥,YNM-RGD(OCH3)2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔÆÄÏÃ¹ËØ,YunanmycinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄøîѺϽð¼ÇÒä½ðÊôÖ§¼Ü,NT-stentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á¼¶ñ¹ý¶É,Transition-dioxinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾í»ýµþ¼Ó,convolution/superpositionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ƽ»¬¼¡ÈâÁö,LeiomyosarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äÒ¶Áö,MesenchymomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ì춬°±ËáÌØÒìÐÔ°ëë×°±Ëáµ°°×ø-3,caspase-3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÉäÁÆ·¨/·½·¨,radiotherapy/methodsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÈâÁö,angiosarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Ô×´,tuftedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °ëë×°±ËáÌ춬°±Ëáµ°°×ø-8,Caspase-8Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÃ±£ËÉ,DebaosongÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äƤÁö/ÖÎÁÆ,Mesothelioma/therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 90ïÈ,90SrÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EOMAϸ°û,EOMAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¬ÉùÐĶ¯Í¼Ãè¼ÆÊõ,EchocadiographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ˨ÈûÓ²»¯,embolo-sclerotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÖÜϸ°ûÁö,HemangiopericytomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔÓºÏÐÔȱʧ,loss of heterozygosityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔÓºÏÐÔ¶ªÊ§,loss of heterozygosityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºË»ùÖÊ,nuclear matrixÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« bcr/ablÈںϻùÒò,bcr/abl fusion geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û±íÃæ,cell surfaceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« nm23µ°°×,nm23 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¯ÁÆ,ChemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÒ©ÄÍÒ©Ïà¹Øµ°°×ÖÊÀà,Multidrug Resistance-Associated ProteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÖÂþÐÔ´óBϸ°ûÁܰÍÁö,diffuse large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔËèϸ°ûÐÔ°×Ѫ²¡,Acute myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«